Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

February 17, 2022

Study Completion Date

February 19, 2023

Conditions
Bone Marrow Failure SyndromeThalassemiaSickle Cell DiseaseDiamond Blackfan AnemiaAcquired Neutropenia in NewbornAcquired Anemia HemolyticAcquired ThrombocytopeniaHemophagocytic LymphohistiocytosesWiskott-Aldrich SyndromeChronic Granulomatous DiseaseCommon Variable ImmunodeficiencyX-linked Lymphoproliferative DiseaseSevere Combined ImmunodeficiencyHurler SyndromeMannosidosisAdrenoleukodystrophy
Interventions
DRUG

Thiotepa--single daily dose

Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.

DRUG

Thiotepa--escalated dose

Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.

Trial Locations (1)

32608

UF Health Shands Children's Hospital, Gainesville

All Listed Sponsors
collaborator

Live Like Bella Pediatric Cancer Research

OTHER

lead

University of Florida

OTHER

NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation | Biotech Hunter | Biotech Hunter